(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

TRENTON, N.J. (AP) — Merck & Co. has agreed to pay $688 million to settle two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster ...

This special report examines a new oral cholesterol medication, Enlycetide, developed by Merck. The pill, an investigational PCSK9 inhibitor, has shown significant results in Phase 3 trials by ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in morning trading even without disclosing data that would show how the medication ...

Merck has been hit with an antitrust action in New Jersey federal court, which claimed that the company entered into an anti-competitive settlement agreement and an unlawful business arrangement in ...

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral ...

Merck has to more heavily rely on top selling pharmaceuticals now that Singulair's off patent. Some of those drugs remain strong enough to carry the extra weight, but others struggle to stay afloat.

NEW YORK (Reuters) - Confidence in Merck & Co's earnings prospects withered on Tuesday, along with its stock price, after U.S. regulators surprisingly rejected the drugmaker's treatment to raise ...

Merck said it will continue studying the prospects of a new drug to treat cholesterol despite the skepticism surrounding the class of medicines triggered late last year by Pfizer's failure with a ...

(Reuters) - A large study of a new type of cholesterol medicine from Merck & Co Inc found it cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat ...